PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers

被引：2
|
作者：
Stebbing, Justin [1 ]
Ellis, Paul [2 ,3 ]
Tutt, Andrew [4 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Oncol & Surg, London W12 0NN, England
[2] Guys & St Thomas NHS Trust, Dept Oncol, London, England
[3] Kings Coll Hosp, London, England
[4] Guys Hosp, Breakthrough Breast Canc Res Unit, Kings Hlth Partners AHSC, London SE1 9RT, England
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 04期
关键词：
breast cancer; BRCA; PARP inhibitor; triple negative; POLY(ADP-RIBOSE) POLYMERASE; RESISTANCE; DNA; REPAIR; MUTATIONS; TUMORS; BRCA1;
D O I：
10.2217/FON.10.27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：485 / 486
页数：2
相关论文
共 50 条
  • [21] Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours
    Wiggins, George A. R.
    Walker, Logan C.
    Pearson, John F.
    CANCERS, 2020, 12 (10) : 1 - 17
  • [22] Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America
    Josef S. Herzog
    Yanin Chavarri-Guerra
    Danielle Castillo
    Julio Abugattas
    Cynthia Villarreal-Garza
    Sharon Sand
    Jessica Clague-Dehart
    Rosa M. Alvarez-Gómez
    Talia Wegman-Ostrosky
    Alejandro Mohar
    Pamela Mora
    Azucena Del Toro-Valero
    Adrian Daneri-Navarro
    Yenni Rodriguez
    Marcia Cruz-Correa
    Patricia Ashton-Prolla
    Bárbara Alemar
    Rosa Mejia
    Lenny Gallardo
    Robin Shaw
    Kai Yang
    Aleck Cervantes
    Kevin Tsang
    Bita Nehoray
    Hugo Barrera Saldana
    Susan Neuhausen
    Jeffrey N. Weitzel
    npj Breast Cancer, 7
  • [23] Reply to Palacios et al., "ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers"
    Jenkins, RB
    Adem, C
    Couch, F
    Hartmann, LC
    GENES CHROMOSOMES & CANCER, 2005, 42 (02): : 206 - 206
  • [24] Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history
    Rebbeck, TR
    Wang, YT
    Kantoff, PW
    Krithivas, K
    Neuhausen, SL
    Godwin, AK
    Daly, MB
    Narod, SA
    Brunet, JS
    Vesprini, D
    Garber, JE
    Lynch, HT
    Weber, BL
    Brown, M
    CANCER RESEARCH, 2001, 61 (14) : 5420 - 5424
  • [25] PTEN alterations in sporadic and BRCA1- associated triple negative breast carcinomas
    Jones, Natalie
    Gros, Audrey
    Velasco, Valerie
    Dapremont, Valerie
    Brouste, Veronique
    Gastaldello, Bernadette
    Debled, Marc
    de Lara, Christine Tunon
    Bonnet, Francoise
    Barouk-Simoner, Emmanuelle
    Bubien, Virginie
    Venat, Laurence
    MacGrogan, Gaetan
    Longy, Michel
    Sevenet, Nicolas
    CANCER GENETICS, 2022, 264 : 8 - 15
  • [26] Effectiveness of microRNA expressions and PARP inhibitors for triple-negative breast cancer with BRCA1 mutations
    Sasaki, Akiko
    Tsunoda, Yuko
    Tsuji, Mayumi
    Udaka, Yuko
    Oyamada, Hideto
    Oguchi, Katsuji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 170P - 170P
  • [27] Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer
    Gupta, Tanya
    Vinayak, Shaveta
    Telli, Melinda
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 51 - 56
  • [28] Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer
    Tanya Gupta
    Shaveta Vinayak
    Melinda Telli
    Breast Cancer Research and Treatment, 2023, 197 : 51 - 56
  • [29] BRCA1- and BRCA2- associated breast carcinomas [BRCA1- und BRCA2-assoziierte Mammakarzinome.]
    Ahrens P.
    Kreipe H.H.
    Der Pathologe, 2009, 30 (Suppl 2): : 207 - 209
  • [30] Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands
    Vencken, P. M. L. H.
    Reitsma, W.
    Kriege, M.
    Mourits, M. J. E.
    de Bock, G. H.
    de Hullu, J. A.
    van Altena, A. M.
    Gaarenstroom, K. N.
    Vasen, H. F. A.
    Adank, M. A.
    Schmidt, M. K.
    van Beurden, M.
    Zweemer, R. P.
    Rijcken, F.
    Slangen, B. F. M.
    Burger, C. W.
    Seynaeve, C.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2036 - 2042
12345